TZIELD Drug Profile

✉ Email this page to a colleague

Summary for Tradename: TZIELD

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TZIELD

Recent Clinical Trials for TZIELD

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Vanderbilt University Medical Center	EARLY_PHASE1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	EARLY_PHASE1

See all TZIELD clinical trials

Pharmacology for TZIELD

Mechanism of Action	CD3-directed Antibody Interactions
Established Pharmacologic Class	CD3-directed Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TZIELD Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TZIELD Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TZIELD Derived from Patent Text Search

No patents found based on company disclosures

TZIELD Market Dynamics, Financial Trajectory, Exclusivity, and Competitive Risk

Last updated: October 5, 2026

TZIELD, or teplizumab-mzwv, is the first disease-modifying therapy approved to delay progression from stage 2 type 1 diabetes to stage 3 clinical disease. The drug has a high per-course price, a narrow but expanding eligible population, and a commercialization model that depends on screening, infusion capacity, payer authorization, and earlier diagnosis. Sanofi’s acquisition of Provention Bio for approximately $2.9 billion transferred TZIELD into a global specialty-care portfolio and created a larger commercial platform, but it also raised the requirement for sustained market development.[1]

What is TZIELD and what did the FDA approve?

TZIELD is an anti-CD3 monoclonal antibody administered by intravenous infusion over 14 consecutive days. The FDA approved it on November 17, 2022, for adults and pediatric patients aged 8 years and older with stage 2 type 1 diabetes to delay progression to stage 3 disease.[2]

Attribute	TZIELD
Active ingredient	Teplizumab-mzwv
Manufacturer	Sanofi
Original developer	Provention Bio
FDA approval	November 17, 2022
BLA	761183
Approved population	Adults and children aged 8 years or older with stage 2 type 1 diabetes
Administration	14 consecutive daily intravenous infusions
Primary benefit	Delays onset of stage 3 type 1 diabetes
Pivotal study	TrialNet TN-10
Median delay in stage 3 disease	Approximately 50 months with TZIELD versus approximately 25 months with placebo in the pivotal trial
Regulatory pathway	Biologics license application under the Public Health Service Act

The pivotal TrialNet TN-10 study enrolled relatives of individuals with type 1 diabetes who had multiple islet autoantibodies and dysglycemia, the defining characteristics of stage 2 disease. The FDA label reported that 45% of treated patients and 72% of placebo patients developed stage 3 disease during the study period.[2]

How large is the TZIELD addressable market?

The commercial market is determined less by the total type 1 diabetes population than by the number of people identified during stage 2 disease.

The United States has a large potential screening population, including relatives of patients with type 1 diabetes and people identified through population-based screening. The immediate treated population is smaller because stage 2 disease requires confirmation of multiple autoantibodies and abnormal glucose regulation.

Market funnel

Market stage	Commercial implication
General population at risk	Large but difficult to identify without screening
Islet autoantibody-positive individuals	Requires laboratory testing and longitudinal monitoring
Stage 2 type 1 diabetes	Core approved TZIELD population
Eligible patients aged 8 or older	Initial treatment population under the current label
Patients receiving infusion therapy	Constrained by referral, reimbursement, and infusion capacity

The market is therefore a screening-conversion market. Sales growth depends on increasing the number of people diagnosed before symptomatic stage 3 disease, not only on converting existing insulin users.

The strongest near-term channels are TrialNet, pediatric endocrinology networks, diabetes centers, primary-care referral systems, and population-screening initiatives. The Centers for Disease Control and Prevention and JDRF have promoted broader type 1 diabetes screening, while the American Diabetes Association has recognized staging based on autoantibodies and glycemic abnormalities.[3][4]

What is the financial trajectory for TZIELD?

TZIELD’s financial trajectory has three phases:

An initial specialty launch with limited physician awareness and complex reimbursement.
A scale-up period driven by expanded screening and treatment-center adoption.
A mature market in which broader screening and potential label expansion determine whether sales approach blockbuster levels.

Provention’s acquisition by Sanofi closed on April 27, 2023. Sanofi paid approximately $2.9 billion, or $25 per share in cash, after initially agreeing to acquire Provention for $10.64 per share and later increasing the offer.[1][5]

The acquisition price reflected the strategic value of a first-in-class preventive therapy, not established commercial revenue. TZIELD had entered the market only months earlier, leaving Sanofi responsible for building the treatment infrastructure.

Revenue drivers

The principal revenue variables are:

Number of stage 2 patients identified.
Percentage of eligible patients referred for treatment.
Payer approval rate.
Number of operational infusion sites.
Completion rate for the 14-day course.
Physician willingness to treat before symptoms appear.
Expansion into younger age groups or additional high-risk populations.
International reimbursement and regulatory approvals.

Sanofi reports TZIELD within its specialty-care business and has not consistently provided a fully disaggregated annual revenue history comparable to its largest standalone products. Public company filings and earnings materials emphasize launch progression, patient identification, access, and treatment-center expansion rather than a complete product-level revenue bridge.[6]

Pricing and gross-revenue potential

The U.S. list price has been reported at approximately $13,850 per 2 mg vial. A full 14-day course can produce a list-price value near $194,000 before discounts, rebates, patient assistance, and site-of-care economics.[7]

That price creates substantial revenue potential per patient, but it also increases payer scrutiny. The commercial model differs from chronic insulin therapy:

Revenue is concentrated in a short treatment course.
Infusion and monitoring costs affect payer decisions.
Patients may avoid years of insulin use, but the immediate budget impact is high.
The treatment may be reimbursed through pharmacy, medical, or specialty-drug benefit structures depending on the payer.
Hospitals and infusion centers may face operational and inventory requirements.

At list price, 5,000 annual treated patients would imply roughly $970 million in gross course value. Net revenue would be lower after discounts and patient-support programs. The number demonstrates why even a small treated population can support substantial product revenue.

When does TZIELD lose exclusivity?

TZIELD is a biologic, so its core regulatory exclusivity is governed by the Public Health Service Act rather than the small-molecule Hatch-Waxman framework.

The FDA granted TZIELD 12 years of reference-product exclusivity from the date of first licensure, subject to statutory rules and any applicable pediatric extension. On that basis, the primary U.S. biologic exclusivity period runs to approximately November 17, 2034. A qualifying six-month pediatric exclusivity period could extend the relevant protection to approximately May 17, 2035.[2][8]

Protection	Relevant date or status
FDA approval and first licensure	November 17, 2022
Twelve-year reference-product exclusivity	Approximately November 17, 2034
Possible pediatric extension	Approximately six additional months
Biosimilar pathway	Section 351(k) of the Public Health Service Act
Orange Book status	Not listed as a conventional small-molecule product
Purple Book relevance	Yes, as a licensed biologic

The 12-year exclusivity period does not eliminate patent risk. Patents can expire before or after regulatory exclusivity, and a biosimilar applicant may litigate or negotiate around patent claims. The public record should be reviewed patent by patent because a single “TZIELD expiration date” does not capture formulation, manufacturing, antibody, dosing, or method-of-use rights.

What is the Orange Book and Purple Book status of TZIELD?

TZIELD is not a traditional Orange Book product because it is a biologic licensed under a BLA. The relevant FDA reference is the Purple Book, which identifies licensed biological products and biosimilar relationships.[9]

A future biosimilar applicant would generally use the 351(k) pathway. That process includes a patent-information exchange commonly called the “patent dance,” although participation and litigation timing depend on the applicant’s conduct and the asserted patents.

Paragraph IV challenges

A conventional Paragraph IV certification is associated with the Hatch-Waxman abbreviated new drug application system for small-molecule products. It is not the standard pathway for challenging a BLA biologic. A future TZIELD biosimilar challenge would more likely involve:

A 351(k) biosimilar application.
Patent disclosures and exchanges under the Biologics Price Competition and Innovation Act.
Declaratory judgment or patent litigation.
FDA exclusivity timing.
Patent challenges involving composition, manufacturing, formulation, or method-of-use claims.

As of the available public record through mid-2024, no approved TZIELD biosimilar had entered the U.S. market.

What patents and intellectual-property rights protect TZIELD?

The commercial protection for TZIELD can include several patent categories:

Anti-CD3 antibody composition claims.
Humanized or modified antibody sequence claims.
Treatment methods for delaying stage 3 type 1 diabetes.
Dosing schedules and treatment regimens.
Formulation and stability claims.
Manufacturing and cell-line claims.
Combination or patient-selection claims.

The principal commercial barrier is likely the combination of regulatory exclusivity and method-of-use protection rather than one universally controlling patent. Because TZIELD is administered for a preventive indication, method-of-use claims can be commercially important if they cover treatment of stage 2 patients, biomarker-defined populations, or dosing schedules.

Patent-strength assessment

Factor	Assessment
Regulatory exclusivity	Strong through approximately 2034, subject to statutory extensions
Biosimilar timing	Limited by 12-year reference-product exclusivity
Method-of-use protection	Potentially important because the approved use is highly defined
Formulation protection	Relevant to product stability and manufacturing
Manufacturing barriers	Meaningful for a complex monoclonal antibody
Substitution risk	Lower than for ordinary generics because TZIELD is a biologic
Litigation exposure	More likely to arise near biosimilar development or label expansion

The principal weakness is that a single indication limits the value of method-of-use rights. If competing anti-CD3 therapies demonstrate similar effects, they may avoid direct infringement by using different molecules, regimens, or patient populations.

Which companies challenge TZIELD commercially?

No direct generic competitor can substitute for TZIELD through an ordinary ANDA. The competitive field is divided into three groups.

Competing disease-modifying therapies

Other anti-CD3 or immune-modulating therapies could compete if they delay stage 3 diabetes, reduce insulin dependence, or produce durable disease modification. Their risk depends on clinical efficacy, dosing burden, safety, and regulatory labeling.

Screening and monitoring alternatives

Screening programs are not drug competitors, but they determine TZIELD’s market size. Earlier identification increases the number of treatable patients. Without screening, many patients present only after symptomatic stage 3 disease, when the current TZIELD indication no longer applies.

Standard management after diagnosis

Insulin, continuous glucose monitoring, automated insulin delivery, and diabetes education remain the standard after stage 3 disease develops. TZIELD competes for healthcare budgets by offering delayed disease onset rather than immediate glucose control.

What generic launch risks exist for TZIELD?

The near-term generic-launch risk is low. The relevant future threat is biosimilar entry after regulatory exclusivity and patent barriers decline.

Base-case launch scenario

A likely U.S. sequence is:

Continued branded commercialization through the early 2030s.
Biosimilar development activity before expiration of regulatory exclusivity.
Patent litigation or negotiated licensing near the end of the exclusivity period.
Initial biosimilar entry only if the market is large enough to justify clinical, manufacturing, and litigation costs.

The economics of biosimilar entry are less attractive when the treated population is small. TZIELD’s high price improves the revenue opportunity, but the 14-day administration course and limited diagnosed population may reduce the scale available to multiple competitors.

A biosimilar could compete on price, payer contracting, and infusion-provider economics. It would not necessarily produce the steep price erosion associated with small-molecule generics.

What regulatory and commercial developments could expand TZIELD sales?

The most valuable expansion opportunities are:

Approval for children younger than 8 years.
Treatment of broader high-risk populations beyond relatives of patients with type 1 diabetes.
Earlier stage 1 disease if clinical evidence supports intervention before dysglycemia.
Additional non-U.S. approvals and reimbursement.
Use in newly diagnosed patients to preserve beta-cell function.
Integration with population screening and primary-care referral programs.
Shorter or more convenient dosing regimens.

Each expansion has different evidentiary requirements. The stage 2 indication is commercially attractive because the disease process is identifiable before clinical symptoms. Earlier treatment could expand the population materially, but it would require a favorable benefit-risk profile in patients who may not develop symptomatic diabetes for years.

How does TZIELD compare with conventional type 1 diabetes treatment?

Category	TZIELD	Conventional insulin management
Treatment timing	Before stage 3 disease	After clinical diagnosis
Objective	Delay disease progression	Control blood glucose
Administration	14-day IV course	Lifelong insulin therapy
Patient population	Stage 2 patients aged 8 or older	Patients with stage 3 type 1 diabetes
Revenue model	High one-time course value	Recurring chronic-treatment revenue
Infrastructure	Infusion center and monitoring	Pharmacy, devices, and diabetes supplies
Clinical uncertainty	Not all stage 2 patients progress at the same rate	Required for established insulin deficiency
Competitive basis	Disease modification	Glucose control and delivery technology

TZIELD’s commercial value is tied to delaying a major chronic disease burden. Its economic argument is strongest for patients at high short-term risk of progression, especially children and adolescents whose treatment delay could reduce disruption to school, work, and family life.

Key Takeaways

TZIELD is the first FDA-approved therapy to delay stage 3 type 1 diabetes.
Sanofi acquired Provention Bio for approximately $2.9 billion in 2023, making TZIELD a strategic specialty-care asset.
The product has a high U.S. course value, reported at approximately $194,000 before discounts and assistance.
Commercial growth depends on screening and diagnosis of stage 2 patients.
The drug has approximately 12 years of U.S. reference-product exclusivity from November 17, 2022, with a possible pediatric extension.
TZIELD is a biologic and does not follow the conventional Orange Book Paragraph IV generic pathway.
The main future threat is biosimilar competition, not ordinary generic substitution.
Patent value is likely concentrated in antibody, method-of-use, formulation, dosing, and manufacturing claims.
Infusion logistics, payer authorization, and limited disease awareness are the main near-term market constraints.
Label expansion and population screening will determine whether TZIELD becomes a major specialty-care product or remains a high-value therapy for a relatively narrow diagnosed population.

FAQs

Is TZIELD a one-time treatment?

TZIELD is administered as a 14-day consecutive intravenous treatment course. The FDA-approved regimen is not a lifelong recurring therapy, although retreatment and use in other disease stages remain subject to clinical evidence and regulatory authorization.

Can TZIELD replace insulin?

No. TZIELD delays progression to stage 3 type 1 diabetes. It does not replace insulin for patients who already have established clinical disease requiring insulin therapy.

Does TZIELD have an approved indication for stage 1 type 1 diabetes?

No. The FDA indication is stage 2 type 1 diabetes in adults and children aged 8 years or older. Use in stage 1 disease would require supporting evidence and regulatory approval.

Will a TZIELD biosimilar be interchangeable with the originator?

Not automatically. Interchangeability is a separate FDA designation from biosimilarity. A biosimilar applicant would need to satisfy the applicable FDA requirements for an interchangeable product.

Why is TZIELD difficult to commercialize despite its high price?

The target population must be identified before symptoms appear, which requires autoantibody testing, glucose monitoring, specialist referral, payer approval, and access to a 14-day infusion program. Those steps limit patient throughput even when the per-course price is high.

References

Sanofi. (2023, April 27). Sanofi completes acquisition of Provention Bio, Inc.
U.S. Food and Drug Administration. (2022, November 17). FDA approves first drug that can delay onset of type 1 diabetes.
American Diabetes Association Professional Practice Committee. (2024). 2. Diagnosis and classification of diabetes: Standards of care in diabetes - 2024. Diabetes Care, 47(Supplement 1).
Centers for Disease Control and Prevention. (2023). Type 1 diabetes screening and prevention resources.
Provention Bio, Inc. (2023). Definitive merger agreement with Sanofi.
Sanofi. (2024). Universal registration document and annual financial report 2023.
Sanofi. (2023). TZIELD U.S. product and access information.
Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.

More… ↓

⤷ Start Trial